• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    HC Wainwright initiated coverage on F-star Therapeutics with a new price target

    3/8/21 8:24:40 AM ET
    $FSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FSTX alert in real time by email
    HC Wainwright initiated coverage of F-star Therapeutics with a rating of Buy and set a new price target of $35.00
    Get the next $FSTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FSTX

    DatePrice TargetRatingAnalyst
    7/15/2022$35.00 → $7.00Buy → Neutral
    H.C. Wainwright
    11/18/2021$15.00Buy
    Ladenburg Thalmann
    8/17/2021$39.00 → $35.00Outperform
    SVB Leerink
    7/8/2021$39.00Outperform
    SVB Leerink
    More analyst ratings

    $FSTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

      Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

      7/8/24 8:15:00 AM ET
      $PIRS
      $TTOO
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.

      invoX Pharma Limited ("invoX"), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that it has successfully completed the acquisition of F-star Therapeutics, Inc. ("F-star") (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, for an aggregate cash consideration of approximately $161 million (or $7.12 per share). F-star is currently executing Phase 2 trials in Europe and the U.S. in patients with PD-1 acquired resistant head and neck cancer, and in checkpoint inhibitor-naïve patients with non-small cell lung cancer (

      3/8/23 7:30:00 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by F-star Therapeutics Inc.

      15-12G - F-star Therapeutics, Inc. (0001566373) (Filer)

      3/20/23 9:06:42 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by F-star Therapeutics Inc.

      EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)

      3/14/23 12:15:07 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by F-star Therapeutics Inc.

      EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)

      3/14/23 12:15:12 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Kayitalire Louis returned $178,135 worth of shares to the company (25,019 units at $7.12), closing all direct ownership in the company to satisfy tax liability

      4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

      3/9/23 9:21:33 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Forster Eliot returned $526,588 worth of shares to the company (73,959 units at $7.12), closing all direct ownership in the company (for withholding tax)

      4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

      3/9/23 9:20:14 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Klein Pamela M.

      4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

      3/9/23 9:18:56 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • F-star Therapeutics downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded F-star Therapeutics from Buy to Neutral and set a new price target of $7.00 from $35.00 previously

      7/15/22 7:26:02 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann resumed coverage on F-star Therapeutics with a new price target

      Ladenburg Thalmann resumed coverage of F-star Therapeutics with a rating of Buy and set a new price target of $15.00

      11/18/21 9:22:57 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on F-star Therapeutics with a new price target

      SVB Leerink reiterated coverage of F-star Therapeutics with a rating of Outperform and set a new price target of $35.00 from $39.00 previously

      8/17/21 6:30:02 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Financials

    Live finance-specific insights

    See more
    • invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.

      invoX Pharma Limited ("invoX"), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that it has successfully completed the acquisition of F-star Therapeutics, Inc. ("F-star") (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, for an aggregate cash consideration of approximately $161 million (or $7.12 per share). F-star is currently executing Phase 2 trials in Europe and the U.S. in patients with PD-1 acquired resistant head and neck cancer, and in checkpoint inhibitor-naïve patients with non-small cell lung cancer (

      3/8/23 7:30:00 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

      Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and Commercialize a Novel Next-Generation Immuno-Oncology Bispecific Antibody TherapeuticFS118 Cleared the Futility Hurdle for the Initial Stage of the Head and Neck Acquired Resistance Cancer Trial Initiation of Combination Dosing with FS120 and KEYTRUDA® in Patients with Advanced Cancers under Supply Agreement with MSD Company Will Not be Hosting Q2 2022 Earnings Conference Call Due to the Pending Transaction with invoX Pharma CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE)

      8/11/22 8:00:00 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Four Clinical Readouts Anticipated Throughout 2022 Mechanistic Data on FS118 Demonstrating Shedding Mechanism and LAG-3 Reduction Presented at the 2022 American Association for Cancer Research (AACR) Annual MeetingCompany To Host Conference Call Today at 9:00 a.m. EDT CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer, today announced first quarter 2022 financial results and provided a corporate update. "This year is one of the most important yea

      5/10/22 8:00:00 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by F-star Therapeutics Inc.

      SC 13G - F-star Therapeutics, Inc. (0001566373) (Subject)

      3/17/23 4:23:46 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by F-star Therapeutics Inc. (Amendment)

      SC 13G/A - F-star Therapeutics, Inc. (0001566373) (Subject)

      2/14/23 4:06:44 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by F-star Therapeutics Inc. (Amendment)

      SC 13G/A - F-star Therapeutics, Inc. (0001566373) (Subject)

      2/14/23 4:02:47 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

      Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

      7/8/24 8:15:00 AM ET
      $PIRS
      $TTOO
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • F-star Therapeutics Appoints James Sandy as Chief Development Officer

      CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that James Sandy has been appointed as Chief Development Officer, effective today. Mr. Sandy will lead the clinical development and advancement of F-star's pipeline. "We are delighted to welcome James to F-star," said Eliot Forster, CEO of F-star Therapeutics, Inc. "James brings an unparalleled depth of experience in drug development in oncology and a strong track record of enhancing and accelerating clin

      3/1/22 8:00:00 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care